XPH
State Street SPDR S&P Pharmaceuticals ETF
SPDR Pharmaceuticals ETF objective is to replicate as closely as possible the performance of the S&P Pharmaceuticals Select Industry Index, an equal-weighted index.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 469.9 M
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Jun 19, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| VERADERMICS INC | 2.8 % |
| XERIS BIOPHARMA HOLDINGS INC | 2.8 % |
| PACIRA PHARMACEUTICALS INC | 2.5 % |
| ELI LILLY & CO | 2.5 % |
| AMNEAL PHARMACEUTICALS, INC. CLASS A | 2.5 % |
| VIATRIS, INC. | 2.3 % |
| MAZE THERAPEUTICS INC | 2.3 % |
| LIGAND PHARMACEUTICALS-CL B | 2.2 % |
| ROYALTY PHARMA PLC CLASS A | 2.2 % |
| PERRIGO CO | 2.2 % |
Constituent Breakdown
| Number of holdings | 57 |
| Herfindahl-Hirschman Index | 186 |
| Wgt avg mkt cap (mns) | $57,220 |
| Large cap (>$10bn) | 22.6% |
| Mid cap ($2-10bn) | 27.9% |
| Small cap (<$2bn) | 39.7% |
| Developed mkts. | 94.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 89.8 % |
 |
IRELAND | 4.0 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 16.1% | 35.6% | 21.0% | 17.8% | 6.5% | 3.9% | 6.9% | 7.3% |
| Dividend Yield | 0.3% | 0.6% | 1.0% | 1.3% | 1.3% | 1.0% | 1.8% | 1.8% |
| Total Returns | 16.4% | 36.2% | 22.0% | 19.1% | 7.8% | 4.9% | 8.7% | 9.1% | Ann. Volatility | 23.8% | 23.2% | 22.7% | 21.1% | 21.2% | 22.1% | 22.2% | 22.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.78 | 19% |
| MSCI EAFE | 0.72 | 24% |
| MSCI Emg Mkts | 0.32 | 12% |
Liquidity Measures
| Avg. volume (000) | 225 |
| ADV traded (mns) | $14 |
| Turnover | 3.0% |
| Avg. Bid/Ask (% of price) | 0.18% |
Technical Indicators
| 30d moving avg. (EMA) | $64.59 |
| Relative strength (RSI) | 47 |
| MACD/Signal | -0.39/-0.71 |
| Bollinger Bands (Upper/Lower) | $65.50/$61.58 |
| Short interest (% of AUM) | 8.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XPH |
Expenses vs. XPH |
ALTAR Score™ vs. XPH |
|---|---|---|---|---|
| IHE | iShares U.S. Pharmaceuticals ETF | 38.6% | +2 bp | +6.4% |
| PJP | Invesco Pharmaceuticals ETF | 37.4% | +23 bp | +8.1% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 20.2% | +25 bp | +6.7% |
| PPH | VanEck Pharmaceutical ETF | 17.8% | +1 bp | +8.0% |
| SBIO | ALPS Medical Breakthroughs ETF | 17.2% | +15 bp | -16.3% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 15.4% | -6 bp | +3.6% |
| ASD | Defiance Autism Impact ETF | 14.4% | +44 bp | +3.5% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 13.3% | +30 bp | -0.1% |
| FXH | First Trust Health Care AlphaDEX Fund | 13.1% | +26 bp | +6.2% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 12.8% | -22 bp | +6.8% |
Risk and Returns: XPH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.0%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,388 funds in the US Equity category with an average
ALTAR Score™ of 5.7% and a standard deviation
of 2.1%. XPH's ALTAR Score™ is approximately -3.2 standard
deviations above the category average. This places XPH in the 1st percentile
among funds in the category.
Sell-Side Consensus
$81.73
PRICE TARGET
+30.5%
UPSIDE